Biomedical Engineering Reference
In-Depth Information
161. Rathore AS. (2009) Follow-on protein products: scientific
issues, developments and challenges. Trends Biotechnol.
27(12), 698-705.
162. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ
D. (2011) Aggregation, stability, and formulation of human
antibody therapeutics. In: Advances in Protein Chemistry and
Structural Biology, Academic Press, 41-61.
163. Baumann A. (2009) Nonclinical development of biopharma-
ceuticals. Drug Discov. Today 14(23-24), 1112-1122.
164. Dixit R, Boelsterli UA. (2007) Healthy animals and animal
models of human disease(s) in safety assessment of human
pharmaceuticals, including therapeutic antibodies. Drug
Discov. Today 12(7-8), 336-342.
165. Bussiere JL, Martin P, Horner M, Couch J, Flaherty M,
Andrews L, et al. (2009) Alternative strategies for toxicity
testing of species-specific biopharmaceuticals. Int. J. Toxicol.
28(3), 230-253.
166. Chen X, Lee H-F, Zaro JL, Shen W-C. (2011) Effects of
receptor binding on plasma half-life of bifunctional transfer-
rin fusion proteins. Mol. Pharm. 8(2), 457-465.
167. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT.
(2010) The safety and side effects of monoclonal antibodies.
Nat. Rev. Drug Discov. 9(4), 325-338.
168. Roberts SA, Woodnutt G, Bradshaw CW, Gad SC. (2010)
Strategy considerations for developing the preclinical safety
testing programs for protein scaffold therapeutics. In: Phar-
maceutical Sciences Encyclopedia. John Wiley & Sons, Inc.,
pp. 1-16.
169. Beck A, Reichert JM. (2011) Therapeutic Fc-fusion proteins
and peptides as successful alternatives to antibodies. MAbs
3(5), 415-416.
170. Bokemeyer C. (2010) Catumaxomab-trifunctional anti-
EpCAM antibody used to treat malignant ascites. Expert
Opin. Biol. Ther. 10(8), 1259-1269.
171. Hiller A. (2009) Fast growth foreseen for protein therapeu-
tics. GEN 29(1), 153-155.
172. Langlands B. (2011) Next-generation protein and peptide
therapeutics. Scrip Bus. Insights 1-192.
Search WWH ::
Custom Search